Trial Profile

Pharmacokinetics of Telavancin in Normal and Obese Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telavancin (Primary)
Indications Bacteraemia; Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Osteomyelitis; Skin and soft tissue infections
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

08 Jan 2018 Results published in the Antimicrobial Agents and Chemotherapy
25 Apr 2017 Results assessing pharmacokinetics of fixed dose telavancin presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
25 Apr 2017 According to a Theravance Biopharma media release,data from this trial was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com